Answers are grounded in this paper and cite their sources.
Background: Aesthetic medicine has long operated on a tissue-filling paradigm, treating the visible consequences of aging rather than its biological substrates. Recent advances in epigenetic reprogramming — particularly maturation-phase transient reprogramming (MPTR) — have demonstrated that the Horvath DNA-methylation clock of human dermal fibroblasts can be reversed by approximately 30 years without loss of somatic identity. Translating this in vitro proof-of-concept into a clinically deployable, regulatorily compliant protocol remains an unmet need. Objective: To present the 3D Rejuvenation Code 2.0 clinical model — a three-element, in-vivo protocol that operationalises the F–ECM–AS (Fibroblast–Extracellular Matrix–Activation Synergy) framework and translates MPTR biology into a deliverable aesthetic-and-longevity intervention. Methods: We synthesise peer-reviewed evidence from reprogramming biology, mechanotransduction, dermal senescence, platelet-rich plasma, polydeoxyribonucleotide (PDRN), biomimetic peptides, and cross-linked hyaluronic acid (HA) into a single-visit, four-step clinical architecture. Regulatory compliance is maintained by substituting autologous PRP for unapproved exosome products under FDA 21 CFR 1271 and EMA ATMP frameworks. Results: The protocol operationalises three Core Elements: (1) The Spark (sub-ablative fractional CO2 laser) to clear senescent fibroblast secretory phenotypes (SASP) and induce heat-shock proteins; (2) The Brain (autologous PRP, PDRN, and biomimetic peptides) delivered within a critical 10-minute post-thermal window to supply growth-factor and purinergic A2A receptor instructions; and (3) The Bone (supraperiosteal medium-G' HA boluses) to restore tensional homeostasis and lock the reprogrammed phenotype via the integrin–YAP/TAZ mechanotransduction axis. Conclusion: 3D Rejuvenation Code 2.0 establishes a multi-omic and biomechanical foundation for clinical skin rejuvenation, replacing superficial volumisation with evidence-based cellular and structural reprogramming.
No takes yet. Share an insight, caveat, or question.
AMR ISMAIL (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: